11 Apr. 2019
ANTIBIOTIC RESISTANCE - THE GRIM PROSPECT
The evolution of pathogens is making many medical problems worse. Time to take drug resistance seriously
11 Apr. 2019
UNADDRESSED, SUPERBUGS COULD KILL 'EVERY 3 SECONDS' BY 2050, REPORT SUGGESTS
BioVersys strongly supports the recommendations form Jim O’Neill’s report on AMR. As a company, we are in this game to combat antimicrobial resistance...
11 Apr. 2019
GLOBAL ANTIBIOTICS 'REVOLUTION' NEEDED
Lord Jim O'Neill, who led the Review on Antimicrobial Resistance, said a campaign was needed to stop people treating antibiotics like sweets.
11 Apr. 2019
SUPERBUG REVIEW URGES BIG PHARMA TO 'PAY OR PLAY' ON ANTIBIOTICS
Drug companies should agree to "pay or play" in the urgent race to develop new antibiotics to tackle a global threat of antimicrobial resistance (AMR)...
Recent Media Feeds
- Press Release - BioVersys hires new CDO, Dr. Glenn Dale
- Eurostars Funds IMPACT2 Press Release
- Dr. Gitzinger will be speaking at the UNCTAD/WHO event in Geneva, October 23rd, 2018 from 14:30-17:30 on Fostering investment in the development of new antibacterial treatments
- CARB-X welcomes UK Government and Bill & Melinda Gates Foundation as new partners
- BioVersys successfully closes Series A2 financing round
- October 20th, 2017; BioVersys and Marc Gitzinger were featured in the 3Sat news.
- BEAM Alliance fordert G20 Staaten zu mehr Unterstützung im Kampf gegen tödliche Superkeime auf
- Swiss biopharma BioVersys is collaborating with drug discovery and development CRO Aptuit on the discovery and development of new targets and drug candidates against Gram-negative bacteria, including drug-resistant strains. An existing BioVersys target will be included in the partnership.
- Press Release BEAM Alliance / Biocom AG
- Breaking through the Wall ... A Call for Concerted Action on AB Research and Development
